- Patent Title: Low-molecular-weight holothurian glycosaminoglycan and use thereof
-
Application No.: US17775588Application Date: 2019-11-19
-
Publication No.: US11643478B2Publication Date: 2023-05-09
- Inventor: Yongsheng Jin , Xiujuan Ding , Wu Chen , Xiaoming Li , Junting Sun , Yihao Zhu , Xiaohua Lu , Caijuan Jin , Hua Zhou , Ningxia Wang , Yongbao Li , Qiaoyun Zhou , Jiangen Qian , Xi Chong , Yiming Yao , Yi Jiang
- Applicant: Suzhou Yi-hua Biomedical Technology co., Ltd , Suzhou Ronnsi Pharma Co., Ltd.
- Applicant Address: CN Jiangsu
- Assignee: Suzhou Yi-hua Biomedical Technology co., Ltd,Suzhou Ronnsi Pharma Co., Ltd.
- Current Assignee: Suzhou Yi-hua Biomedical Technology co., Ltd,Suzhou Ronnsi Pharma Co., Ltd.
- Current Assignee Address: CN Jiangsu
- Agency: OPES IP Consulting Co. Ltd
- Priority: CN 1911102517.0 2019.11.12
- International Application: PCT/CN2019/119414 2019.11.19
- International Announcement: WO2021/092979A 2021.05.20
- Date entered country: 2022-05-10
- Main IPC: C08B37/00
- IPC: C08B37/00 ; A61P25/28 ; A61P29/00 ; A61P35/04 ; A61P9/14 ; A61K31/726

Abstract:
Provided is a low-molecular-weight holothurian glycosarninoglycan, with the constituent units thereof being a glucuronic acid group, an N-acetaminogalactose group and a fucose group, and a sulfate ester group or acetyl ester group thereof. Glucuronic acid and N-acetaminogalactose are interconnected via β(1-3) and β(1-4) glucosidic bonds to form a backbone of a disaccharide repeating structural unit, and a fucose group is connected to the backbone as a side chain. On a molar ratio basis, the ratio of the glucuronic acid group:the N-acetaminogalactose group:the fucose group is 1:(0.8-1.2):(0.6-1.2). In the structure of the low-molecular-weight holothurian glycosaminoglycan, 10-30% of glucuronic acid groups are modified, on the 2-position, with a sulfate ester group, and the rest are hydroxyl groups; and a proportion of 10-30% of fucose groups is modified, on the 2-position, with an acetyl ester group, and the rest are hydroxyl or sulfate ester groups. The low-molecular-weight holothurian glycosarninoglycan of the present invention has anti-inflammation, anti-vasculopathy, anti-tumor or anti-tumor-metastasis functions, and the effect of improving learning and memory abilities, and can be used for preparing a related drug or health-care product.
Public/Granted literature
- US20220340690A1 LOW-MOLECULAR-WEIGHT HOLOTHURIAN GLYCOSAMINOGLYCAN AND USE THEREOF Public/Granted day:2022-10-27
Information query